CPRX Share Price

Open 3.16 Change Price %
High 3.20 1 Day -0.04 -1.27
Low 2.99 1 Week 0.15 5.08
Close 3.10 1 Month 0.31 11.11
Volume 900620 1 Year 2.38 330.56
52 Week High 3.20
52 Week Low 0.69
CPRX Important Levels
Resistance 2 3.29
Resistance 1 3.21
Pivot 3.10
Support 1 2.99
Support 2 2.91
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
QQQ 143.96 -0.63%
SIRI 5.83 8.16%
FB 170.44 2.92%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SHOR 7.50 28.21%
OPNT 14.53 27.46%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LPSN 13.50 18.42%
TREE 217.15 18.14%
AXTI 8.80 15.79%
DRYS 1.20 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
IPCI 1.36 -45.38%
DVOX 0.05 -44.44%
GLCH 0.70 -44.00%
PRXI 0.21 -43.24%
More..

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

CPRX Technical Analysis 5
As on 27th Jul 2017 CPRX Share Price closed @ 3.10 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.56 & Strong Buy for SHORT-TERM with Stoploss of 2.52 we also expect STOCK to react on Following IMPORTANT LEVELS.
CPRX Target for July
1st Target up-side 3.17
2nd Target up-side 3.46
3rd Target up-side 3.75
1st Target down-side 2.35
2nd Target down-side 2.06
3rd Target down-side 1.77
CPRX Other Details
Segment EQ
Market Capital 44575204.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.catalystpharma.com
CPRX Address
CPRX
355 Alhambra Circle
Suite 1500
Coral Gables, FL 33134
United States
Phone: 305-529-2522
CPRX Latest News
Interactive Technical Analysis Chart Catalyst Pharmaceutical Partners, Inc. ( CPRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Catalyst Pharmaceutical Partners, Inc.
CPRX Business Profile
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction. As of December 31, 2011, the Company was in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It has identified two market opportunities that can be exploited by pharmacotherapies that inhibit GABA-aminotransferase (GABA-AT): drug addiction and epilepsy.